



## Revisión

### Omega-3 fatty acids and cognitive decline: a systematic review

#### *Omega-3 y deterioro cognitivo: una revisión sistemática*

Amelia Martí<sup>1-3</sup> and Francesca Fortique<sup>1</sup>

<sup>1</sup>Department of Nutrition, Food Science and Physiology. University of Navarra. Pamplona, Spain. <sup>2</sup>Navarra Institute for Health Research (IdiSNA). Pamplona, Spain. <sup>3</sup>Center of Biomedical Research in Physiopathology of Obesity and Nutrition (CIBEROBN). Instituto de Salud Carlos III. Madrid, Spain

### Abstract

In a growing elderly population, mild cognitive impairment (MCI) and age related cognitive decline (ARCD) are increasing in prevalence worldwide. In the search for food compounds able to ameliorate this condition, it has been postulated that n-3 Long chain polyunsaturated fatty acids (n-3 LCPUFA), also known as omega-3, consumption could have a positive effect in the prevention or therapy of these cognitive declines. However, there are contradictory findings in the literature concerning the effects of n-3 LCPUFA on cognitive decline making it difficult to draw a conclusion on this topic. This current systematic review studies the relationship between n-3 LCPUFAs and cognitive status in aged adult and elder populations to determine whether there is or not a positive effect of n-3 LCPUFAs supplementation on cognitive decline. Additionally, we remark how duration periods, different cognitive baseline status in subjects, dosage of n-3 LCPUFAs administration and the presence of other factors might be related to different outcomes. A search of randomized controlled trials (RCTs) related with the relationship between cognitive impairment and n-3 LCPUFA (docosahexaenoic acid, eicosapentaenoic acid or combined) supplementation was conducted through PubMed database from January 2010 to December 2017 following the PRISMA statement. Interventional studies which included aged adults or elder subjects with or without MCI and with no previous intake of fish oil supplements (FOS) were included. Ten out of the fourteen RCTs reviewed showed positive outcome on at least one domain of cognitive function (working memory, executive function, verbal memory, short-term memory, perceptual speed, etc.). This systematic review concludes that omega-3 supplementation might have a positive effect on cognitive function. Thus, n-3 LCPUFAs could be used as a preventive or therapeutic tool for cognitive decline in aged or elder adults.

#### Key words:

Cognitive decline.  
Omega-3  
polyunsaturated fatty acids (n-3 PUFAs).  
Aging. Mild cognitive impairment.

### Resumen

En grupos de población de mayores en constante crecimiento, el deterioro cognitivo asociado o no a la edad incrementa en prevalencia mundialmente. Se ha postulado que el consumo de ácidos grasos de cadena larga n-3 (AGCL n-3), también conocidos como omega-3, podrían tener un efecto positivo en la prevención o tratamiento del deterioro cognitivo. Sin embargo, existen hallazgos contradictorios en la literatura respecto al efecto de los AGCL n-3 sobre la función cognitiva, lo cual hace difícil extraer una conclusión sobre su posible función. La presente revisión sistemática estudia la relación entre los AGCL n-3 y el estado cognitivo en adultos de mediana edad y mayores de 60 años para determinar si hay un efecto positivo de la suplementación con omega-3 en el deterioro cognitivo. Adicionalmente, se hace énfasis en cómo la duración de los ensayos, el estado cognitivo basal de los sujetos, la dosis de AGCL n-3 y la presencia de otros factores pudiesen estar relacionados con los diferentes resultados obtenidos. Una búsqueda de ensayos clínicos aleatorizados relacionados con la relación entre el deterioro cognitivo y la suplementación de AGCL n-3 (ácido docosahexaenoico, ácido eicosapentaenoico o una combinación de los mismos) se llevó a cabo a través de la base de datos PubMed desde enero de 2010 hasta febrero de 2018 siguiendo la metodología PRISMA. Estudios de intervención que incluían sujetos adultos de mediana edad y mayores de 60 años con o sin deterioro cognitivo leve sin que hubieran recibido otros suplementos (aceite de pescado) fueron incluidos. Diez de los 14 ensayos clínicos aleatorizados mostraron una mejora en algún dominio de la función cognitiva (memoria de trabajo, función ejecutiva, memoria verbal, memoria a corto plazo, rapidez de percepción, etc.). Esta revisión sistemática concluye que la suplementación con AGCL n-3 puede tener un efecto positivo en la función cognitiva. De esta manera, podrían ser usados como una medida preventiva o como tratamiento para el deterioro cognitivo.

#### Palabras clave:

Deterioro cognitivo.  
Ácidos grasos de cadena larga omega 3 (AGCL n-3).  
Envejecimiento.  
Deterioro cognitivo leve.

Received: 08/01/2019 • Accepted: 25/03/2019

Martí A, Fortique F. Omega-3 fatty acids and cognitive decline: a systematic review. *Nutr Hosp* 2019;36(4):939-949

DOI: <http://dx.doi.org/10.20960/nh.02496>

#### Correspondence:

Amelia Martí. Department of Nutrition, Food Science and Physiology. Universidad de Navarra. C/ Irunlarrea, 1. 31008 Pamplona, Spain  
e-mail: [amarti@unav.es](mailto:amarti@unav.es)

## INTRODUCTION

Omega-3 fatty acids or n-3 long chained polyunsaturated fatty acids (n-3 LCPUFA) are nutrients mainly found in the diet that could reduce the risk or help in the treatment of cognitive decline. There are three different types of n-3 LCPUFA:  $\alpha$ -linolenic acid (ALA), docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA). Of these, DHA and EPA (in lesser proportion) are important components of the neuronal membranes in the brain (1-3). These n-3 LCPUFAS have been shown to have a major role from the moment of the fetus formation to the aging process and brain senescence (1, 4,5). Brain function, visual development and neural development depend on an adequate n-3 LCPUFA supply (2,6). In fact, a study performed in children yielded beneficial effects from supplementation of n-3 LCPUFA on cognition and motor skills (7).

As humans age, the concentration of n-3 LCPUFAs in the brain decreases, which translates into an increase in the risk of suffering from the negative consequences of neurodegeneration (8-10). Moreover, aging is also linked to damage in the neural tissue due to different cellular processes like chronic mild inflammation (11,12), mitochondrial insufficiency (13), oxidative stress (14-16) and accumulation of  $\beta$ -amyloid (17). Recent evidence suggests that n-3 LCPUFAs have a beneficial effect on the prevention of cognitive decline due to different mechanisms such as anti-inflammatory and antioxidant effects and others that slow down or "compensate" neurodegeneration (10).

Even though human aging is a physiological process, it involves the global degeneration of motor and cognitive abilities due to different biological and chemical processes. As humans age the brain shrinks, vasculature gets damaged and neurotransmitters and hormone levels change, which can be globally translated into cognitive decline (18). Deterioration throughout the lifespan due to normal aging is referred to as age related cognitive decline (ARCD) (19). On the other hand, mild cognitive impairment (MCI) is the term used to identify the state of cognitive function prior to dementia, which is different from normal ageing, being it an intermediate stage between the two (20). However, there is no agreement in the field for early detection of MCI (21). As research work on MCI continues to increase, lack of consensus has arisen concerning its identification in a patient and its specific boundaries (22). According to the first key symposium on MCI conducted by the International Working Group on Mild Cognitive Impairment, there are three key criteria for a general detection of MCI: "(i) The person is neither normal nor demented; (ii) there is evidence of cognitive deterioration shown by either objectively measured decline over time and/or subjective report of decline by self-report and/or informant report in conjunction with objective cognitive deficits; and (iii) activities of daily living are preserved and complex instrumental function are either intact or minimally impaired" (22).

A growing population of elder subjects and unhealthy diets are nowadays leading to the increase in the prevalence of different age-related diseases, being cognitive impairment one of the most prevalent ones (23-25). Cognitive decline is considered as inevitable, however, its magnitude is highly variable and affected by different pathogenic processes such as hypertension, diabetes


and cardiovascular risk factors (26-28). Cognition can also be impaired by other different factors such as decreased physical activity, genetic predisposition, metabolic disorders and unhealthy diet (25,27,29-31). In this context, the beneficial effect of nutrition on cognitive function is a topic of increasing interest (32). Due to the possible positive effects that n-3 LCPUFAs might exert over cognition, several research work were conducted (33-37) in order to explore its possible therapeutic effects. Several clinical studies have explored the association of omega-3 with cognitive impairment. However, conflicting results have been reported (8), making it difficult for the scientific community to draw a conclusion on this topic. In this sense, the main objective of the present work is to review the evidence on the role of n-3 LCPUFAs on cognitive function in aged adult and elderly populations, and to determine whether they can be used as a preventive/therapeutic strategy for cognitive decline in elder populations. Additionally, we also remark how different factors such as duration periods, different cognitive baseline status in subjects, dosage of n-3 LCPUFAs administration and the presence of other factors might be related to different outcomes.

## METHODS

For the elaboration of this systematic review, the standard informative methods corresponding to the PRISMA statement were followed (38). Relevant studies were identified through a search in a scientific database (PubMed). Additional literature searches included the examination of the reference lists of all pertinent/relevant reviews and studies. The studies chosen were published between January 2010 and December 2017. The search strategy was based on the use of terms related to n-3 LCPUFA (*Docosahexaenoic acid* OR *Omega-3 fatty acids* OR *n-3 polyunsaturated fatty acids* OR *DHA*) and their effect on cognition in aged adults (*Cognition* OR *Memory* OR *Mild Cognitive Impairment AND Elderly*).

Randomized controlled trials (RCTs) on the effect of omega-3 supplementation, including DHA and EPA or a combination of both, on cognition and/or memory outcomes in healthy aged adults with or without MCI were included in this review. Studies were excluded when: a) they only used dietary sources for the intervention; b) participants were not in the age range of 45-80 years old; and c) participants were diagnosed with dementia, Alzheimer's disease, cardiovascular diseases or diabetes, or they suffered from other relevant health conditions that might affect cognitive status. Moreover, studies in animals, *in vitro* studies and reviews were also excluded. Studies that only considered the effects of multivitamins including n-3 LCPUFA but not their independent effects (e.g., evaluation of the effect of multivitamin supplementation including omega-3 fatty acids without the evaluation of the effect of omega-3 fatty acids alone) and studies that did not specify the dosage of n-3 LCPUFA used in the intervention were excluded.

The initial search (which included the following filters: five years, human subjects) yielded 127 references, of which 49 were excluded due to initial screening of titles (Fig. 1). Seventy-four full-text articles were left for further screening. The second screening



**Figure 1.**

Flow diagram of the selection of articles related to the effect of omega-3 supplementation on cognitive decline for this systematic review.

consisted in the reading of the Abstracts; 22 articles were excluded because participants were diagnosed with health conditions that could affect their cognition such as dementia, cardiovascular diseases, diabetes, recent strokes or head injuries, Alzheimer's disease, etc., and 21 others due to age ranges different from 45-80 years old. Forty full-text articles were then assessed for eligibility; 24 were excluded because they were not RCTs (cohorts, open label extension studies, etc.), and two were also excluded for other reasons (sub-study and not including number of participants). During the full-text review, nine additional articles were included from the reference list of the studies being reviewed. Finally, 14 interventional studies were included in this synthesis of the current systematic review.

## RESULTS

The main characteristics of the 14 RCTs included in this work are summarized in table I. Six studies were conducted in cognitively healthy adults, four in participants with subjective cognitive impairment/complaints, three in participants with MCI and one with participants with cognitive impairment no dementia (CIND) or Alzheimer's disease (AD). This last study was included because it

analyzed the effects in both the CIND and the AD participants and because participants with AD are 19 out of 57 participants. The interventions ranged from a time period of one month to 12 months with an average of 5.7 months. Four different types of intervention relating the dosage and type of n-3 LCPUFA used were identified. In relation to the type of omega-3 administration, the majority of the interventions consisted of a combined administration of DHA + EPA. Nine studies administered DHA+EPA in a dose range of 252 to 1,500 mg of DHA and 60 to 1,500 mg of EPA. Three studies administered DHA only, in which 252 mg DHA was the minimum dosage and 2,000 mg DHA was the maximum. One study had two fish oil intervention groups, one group had krill oil and the other one sardine oil. Lastly, there was one study that consisted in the administration of 300 mg DHA + 100 mg EPA + 120 mg arachidonic acid (ARA). All studies were conducted in subjects over 45 years of age. Furthermore, ten studies included less than 90 participants. Most of the RCTs were conducted in men and women except two that included men only subjects. Studies were conducted in different countries, such as the European Union, the United States, Japan and China.

Moreover, most of the studies did not mention their statistical power. Nonetheless, ten out of 14 achieved significant results in relation to the positive effect that n-3 LCPUFAs exert on cognition.

**Table 1. Main characteristics of the articles included in this review evaluating the effect of omega-3 supplementation on cognitive decline in elderly populations**

Reference and location	Objective	Sample size	Dose used	Intervention duration	Primary outcome
<b>Healthy subjects</b>					
Nilsson A et al. 2012 (42) Sweden	To evaluate the effects of dietary supplementation with n-3 PUFA on cognitive performance in healthy individuals and to relate cognitive outcome to cardio-metabolic risk parameters	75	1,500 mg EPA + 1,050 mg DHA	2.5 months	Better performance in the Working Memory Test compared with placebo ( $p < 0.05$ )
Stough C et al. 2012 (43) United Kingdom	To study the effects of supplementation with DHA on cognitive function and visual acuity in a healthy aging population	74	252 mg per day DHA + 60 mg EPA	3 months	No significant effects of DHA supplementation on cognitive function
Witte A et al. 2013 (44) Germany	To study the effects of long-chain omega-3 fatty acids in brain function and structure in older adults	65	1,320 mg EPA + 880 mg DHA per day	6.5 months	Enhanced executive functions by 26% Significant increases in regional GM volume compared with placebo
Konagai C et al. 2013 (40) Japan	To investigate the influence of ingestion of krill oil on cognitive function in elderly subjects by using near-infrared spectroscopy and electroencephalography	45	Krill oil (193 mg EPA + 92 mg DHA) or sardine oil (491 mg EPA + 251 mg DHA)	3 months	Significant greater changes in KO and SO group in oxyhemoglobin concentrations in channel 10 (dorsolateral prefrontal cortex) in response to performance of the Working Memory Test compared to the Medium Chain Triglycerides group
ToKuda H et al. 2015 (45) Japan	To evaluate the effects of low doses of LCPUFA supplementation, corresponding with dietary intake, on cognitive function in non-demented elderly participants	115	300 mg of DHA, 100 mg of EPA, and 120 mg of ARA	1 month	Changes in electroencephalograph latency were significantly positive in relation to the placebo group (+13.6 msec) and the LCPUFA group (-1.8 msec) after supplementation
Pase MP et al. 2015 (46) Australia	To determine the effects of fish oil, multivitamin or combined supplementation on a set of cognitive composite scores, including reaction time, cognitive processing speed, short-term memory, and visual memory in healthy adults	160	480 mg EPA + 480 mg DHA	4 months	No effect of treatment on any of the primary cognitive endpoints
<b>Subjects with subjective cognitive impairment/complaints</b>					
Yurko-Mauro K et al. 2010 (47) United States	To determine effects of DHA administration on improving cognitive functions in healthy older adults with cognitive decline (ARCD)	485	900 mg DHA	6 months	Significantly fewer PAL 6 pattern errors with DHA versus placebo at 24 weeks (difference score, -1.63 ± 0.76, $p = 0.03$ ). Improved immediate and delayed verbal recognition memory scores ( $p < 0.02$ )

AD: Alzheimer's disease; ARCD: age related cognitive decline; BOLD: cortical blood oxygen level-dependent activity; CIND: cognitive impairment no dementia; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; FA: fatty acids; FO: fish oils; GM: grey matter; KO: krill oil; MCI: mild cognitive impairment; PAL: CANTAB paired associate learning; SO: sardine oil.

(Continuation in the next page)

**Table 1 (Cont.).** Main characteristics of the articles included in this review evaluating the effect of omega-3 supplementation on cognitive decline in elderly populations

Reference and location	Objective	Sample size	Dose used	Intervention duration	Primary outcome
<b>Subjects with subjective cognitive impairment/complaints</b>					
Jackson P et al. 2016 (48) United Kingdom	To assess the effect of the supplementation with a multinutrient containing FO or DHA-rich FO alone supplement on cerebral hemodynamics and cognitive function in healthy older adults aged 50-70 years with subjective memory complaints	84	896 mg DHA + 128 mg EPA	6 months	No effect of treatment on either cerebral hemodynamics or cognitive function
Boespflug EL et al. 2016 (49) United States	To determine the effects of long-chain omega-3 FA found in FO, including EPA and DHA, on cortical blood oxygen level-dependent (BOLD) activity during a working memory task in older adults with subjective memory impairment	21	1,600 mg EPA + 800 mg DHA	6 months	Improvement in working memory performance and BOLD signal in the posterior cingulate cortex during greater working memory load
McNamara RK et al. 2017 (50) United States	To evaluate the effect on cognitive response of FO, blueberry and combined supplementation in older adults with subjective cognitive impairment	76	1,600 mg EPA + 800 mg DHA	6 months	Reduced cognitive symptoms in everyday activities in the FO group as measured by the dysexecutive test. No effect for motor speed, working memory, learning and retention, and lexical access
<b>Subjects with MCI</b>					
Lee LK et al. 2013 (41) Malaysia	To study the effects of fish oil supplementation on cognitive function in elderly people with MCI	36	1,300 mg DHA and 0.45 mg EPA	12 months	The fish oil group showed significant improvement in short-term and working memory ( $F = 9.890$ ; $p < 0.0001$ ), immediate verbal memory ( $p < 0.05$ ) and delayed recall capability ( $p < 0.05$ )
Phillips MA et al. 2015 (52) United Kingdom	To explore whether omega-3 PUFA supplements providing DHA and EPA benefit cognition and mood in individuals with early CIND and probable AD	76	600 mg EPA and 625 mg DHA	4 months	No effect of omega-3 fatty acid supplementation on cognition

AD: Alzheimer's disease; ARCD: age related cognitive decline; BOLD: cortical blood oxygen level-dependent activity; CIND: cognitive impairment no dementia; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; FA: fatty acids; FO: fish oils; GM: grey matter; KO: krill oil; MCI: mild cognitive impairment; PAL: CANTAB paired associate learning; SO: sardine oil.

(Continuation in the next page)

**Table 1 (Cont.).** Main characteristics of the articles included in this review evaluating the effect of omega-3 supplementation on cognitive decline in elderly populations

Reference and location	Objective	Sample size	Dose used	Intervention duration	Primary outcome
<b>Subjects with MCI</b>					
Zhang Y et al. 2017 (51) China	To determine the effect of DHA supplementation on cognitive function and hippocampal atrophy in elderly subjects with MCI	240	2,000 mg DHA	12 months	Significant enhancement in the Full-Scale Intelligence Quotient ( $p = 0.039$ ), Information ( $p = 0.000$ ), and Digit Span ( $p = 0.000$ ) between DHA-treated <i>versus</i> the placebo group. Total hippocampus volume in DHA group increased by 4%, while decreased by 0.19% in the placebo group. Global cerebral volume showed a greater increase in the intervention group (+0.29%) compared to the control group (+0.12%)
Bo Y et al. 2017 (39) China	To investigate the effect of n-3 PUFA supplementation on cognitive function in the Chinese elderly with MCI	86	480 mg DHA and 720 mg EPA	6 months	Improved total Basic Cognitive Aptitude Test scores, perceptual speed, space imagery efficiency and working memory

AD: Alzheimer's disease; ARCD: age related cognitive decline; BOLD: cortical blood oxygen level-dependent activity; CIND: cognitive impairment no dementia; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; FA: fatty acids; FO: fish oils; GM: grey matter; KO: krill oil; MCI: mild cognitive impairment; PAL: CANTAB paired associate learning; SO: sardine oil.

However, four studies lacked significant positive results. From the studies with positive outcomes, improvements in perceptual speed, space imagery, working memory, episodic memory, learning function, immediate visual memory, short term memory, delayed recall capability, executive functions and cognitive processing speed were observed. Furthermore, working memory was the domain of cognition most commonly enhanced between the studies (39-42).

## DISCUSSION

This review identified 14 RCTs studying the effect that omega-3 supplementation exerts over cognition in aged adult and elder populations.

Ten out of fourteen studies showed a positive association between omega-3 supplementation and cognitive decline. Different study factors may account for differences in results between studies such as study duration, number of participants as well as their cognitive baseline status, dosage and type of n-3 LCPUFA used, diet of the participants, APOE-4 genotype, etc.

Exclusion criteria were similar in all studies, thus the subjects studied could be comparable among them. They excluded participants with history or current neuropsychological disease, psychiatric disease, mental illness and previous intake of FOS. Other exclusion factors that were taken into acquaintance in almost all studies were: depression, diabetes, cardiovascular disease, kidney failure, alcohol or drug abuse, intake of multivitamins previous to the study and use of medications that could affect the outcome of the intervention such as angiotensin-converting-enzyme inhibitor. Another factor that added reliability to these studies was that eleven out of 14 studies reported no significant between group differences and the other three reported studying the differences and adjusting them with statistical analyses such as Student's t, Chi-square test and paired t test.

An important factor that might have affected the results is the cognitive baseline status of the participants. Some of the previous studies that have yielded positive results on n-3 LCPUFA supplementation have mentioned that the positive effects could only be observed in subjects with MCI but not in healthy subjects or those with AD (53). However, this review showed no difference in results based on the main three different baseline statuses: healthy, subjective cognitive impairment/complaints and MCI. It is also important to mention that most of the studies used different tools to measure baseline cognitive status in participants, being the Mini Mental State Examination (MMSE) the most used one. This methodologic difference in assessing cognitive status could influence the effect that n-3 LCPUFAs exert over cognition.

Moreover, they used different tools to assess cognitive improvement in the participants. This may also account for different results since some tools may be more or less accurate as well as having different sensitivities for diverse aspects of cognition. Furthermore, it was mentioned in three studies

(39,41,46) that a possible factor that might have affected results was proficiency in the tests administered to measure cognitive improvements such as the Basic Cognitive Aptitude Tests (BCAT) and the Swinburne University Computerized Cognitive Assessment Battery. Since tests were administered more than once, participants in both groups could have had the practice effect, showing improvement in cognition without necessarily being it so (39).

A rather novel way to measure cognitive improvement is the near infrared spectroscopy (NIRS), which is a non-invasive neuroimaging technique that measures relative changes in oxyhemoglobin concentration in the superficial cortex in response to a localized neural activity. Both Jackson (2016) (48) and Konagai (2013) (40) used the NIRS to measure cognitive function in their studies. However, they obtained conflicting results which might be attributed to the fact that they used different tasks to activate neural activity.

Moreover, the study lead by Yurko-Mauro (2010) (54) consisting in a supplementation of 900 mg of DHA in healthy participants with ARCD was the first to clinically confirm that DHA significantly improves learning functions and episodic memory. Other studies (39,42,44,49) that consisted in a DHA+EPA intervention corroborate the positive results of n-3 LCPUFA supplementation on cognition, which increases the amount of evidence that omega-3 supplements might be used as a nutritional neuroprotective agent. The mechanisms related to the positive effects of omega-3 on cognition are the following (Fig. 2):

1. Enhancement of the brain-derived neurotrophic factor (BDNF) levels (55).
2. Reduction of ARA and its metabolites availability in brain compartments, which contributes to glial and neuronal hyperactivation (55,56).
3. Increase of the antioxidant defenses: reduction of *in vivo* oxidant stress by either direct or indirect pathways (55,57).
4. Increase of phosphatidylserine (PS) concentration in the brain: faster translocation and phosphorylation of protein kinase B (Akt), which increases neuronal survival (58).
5. Synthesis of neuroprotectin D1 (NPD1): a metabolite of DHA which appears to have multiple neuroprotective functions such as up-regulation of anti-apoptotic and down-regulation of pro-apoptotic mediators that modulate cell death (59).
6. Promotion of neurogenesis (60) and improvement in the fluidity in synaptic membranes (61).
7. Increase of a glucose transporter which improves brain glucose transport (15).
8. Improvement of G-protein coupling involved in signal transduction pathways whose deficiency is associated with cognitive deficits (62).

However, not all studies yielded positive results. There are a number of factors involved in the design and methodology of the studies that could have potentially confounded the results. One important confounder is the polymorphisms in APOE (63). It has been found that APOE- $\epsilon$ 4 genotype influences the way n-3 LCPUFA are metabolized (64,65), specifically in the manner DHA is incorporated into the plasma lipids (66,67). However, the exact effect that APOE- $\epsilon$ 4 has over cognition is not clear yet,


even though large epidemiological studies (68-70) testing the influence DHA supplementation has over cognition reported that the benefits linked to DHA were restricted to subjects that were non-carriers of the APOE- $\epsilon$ 4 allele. Although this genotype has been demonstrated to be important in this topic, it was only taken into acquaintance in the study conducted by McNamara et al. (2017) (50) in which it was found that APOE- $\epsilon$ 4 genotype did not affect the n-3 LCPUFA metabolism.

Furthermore, diet is another relevant factor which might have affected results. The diet of participants previous to the study is an important confounder since n-3 LCPUFA are more present in some diets than others, which might affect the cognitive status of the subjects. It should also be considered that there is evidence that the effects of n-3 LCPUFAs on cognitive function have a beneficial effect on short term memory only on people deficient in n-3 LCPUFAs (71). Tokuda et al. (2015) (45) mentioned that one limitation of his study was the fact that Japanese population has a high intake of n-3 LCPUFA for which participants of this study might not be comparable with participants of European or American studies. Moreover, McNamara et al. (2017) (50) as well as Boespflug et al. (2016) (49) applied 3-day diet records during the week before enrolment to characterize the background diet of participants. They also applied the same three-day diet records during week 12 and week 24 (final week). Additionally, an omega-3 dietary intake questionnaire (72) was also administered before starting the intervention to identify the habitual intake of omega-3 in their diet. Other studies mentioned the use of Food Frequency Questionnaires (FFQs). Yurko-Mauro et al. (2010) (47) made use of the FFQ to minimize the potential confounding effect of a diet high in DHA before the study entry. Participants that had a high intake of 200 mg of DHA per day were excluded.

As well as the diet previous to the study, the diet followed during the intervention period in the study is of major importance (40,50). Konagai et al. (2013) (40) also used the FFQ but with the purpose of measuring the nutrient intake of participants during the study. Their results showed no significant differences between the ingestion of any of the nutrients measured by the FFQ which helped attribute the results of the study on the omega-3 supplementation only. Furthermore, we found that only two studies out of fourteen restricted the n-3 LCPUFA intake so that the changes in cognition could only be attributed to the n-3 LCPUFA oil supplementation and not to the n-3 LCPUFAs consumed from the diet which makes their results more reliable.

Intervention duration is a very important factor to take into acquaintance. Shorter intervention periods might not give enough time to the omega-3 to show significant results on cognition (52). However, interventions of one month (45) and of two months and a half (42) showed significant results. Interestingly, both of these studies had a statistical power  $\geq 80\%$ . The RCTs that yielded no results from the intervention all had durations of over two months and a half, which makes the factor duration a less likely confounder factor in the results.

It was also observed that three out of four RCTs with no positive outcome in the intervention had an overall younger age range ( $\approx 63$  years old) of the participants compared to the studies with positive outcomes.



**Figure 2.**  
Possible mechanisms related to omega-3 consumption on cognition.

It could be inferred that older participants benefit more from this kind of intervention although different studies support the idea that early intervention for prevention of worsening of cognitive decline is more effective than an intervention in older participants that already have an evident cognitive decline (73).

Moreover, an interesting study was the one carried out by Nilsson et al. (2012) (42) in which participants acted as their own control since it was a cross-over study. It revealed that a five-week intervention consisting in daily intake of omega-3 from fish oil improved cognitive function in a healthy population. Since the control and intervention group were the same, it annulled

the possibility that between group differences might have been a confounder in the results.

N-3 LCPUFAs effect over cognition have also been assessed in combination with other nutrients relevant to brain function to check for synergic effects that could benefit cognition (48). Two of the reviewed studies tested the effects of a combined supplementation of n-3 LCPUFAs and a multinutrient (46,48), nevertheless, none obtained significant results of the combined omega-3 and multinutrient intervention. Some of the nutrients being used were: ginkgo biloba, vitamin B6, vitamin B12, phosphatidylserine and anthocyanins. Additionally, there was also another study that

investigated the effect of omega-3 alone, in combination of blueberry (BB) powder and of BB powder alone (50). Shukitt-Hale et al. (2015) studied BBs and their relation to neurocognitive function in aging which yielded positive effects (74). However, the study from this review obtained positive results in cognition both from the BB intervention and the one from omega-3 but not from the combined intervention. The reason for which the combined intervention lacked effect is unknown, however, McNamara et al. (2017) stated that one consideration could be that daily, long-term supplementation of omega-3 and BB powder may have sabotaged a beneficial outcome (50).

Moreover, fatty acids (FA) were measured in blood to evaluate the changes in n-3 LCPUFAs concentration in blood. Previous scientific studies have reported a positive relationships between high concentrations of circulating omega-3 FA in blood and cognitive decline (75). Nevertheless, these findings, specifically those referring to verbal fluency, appear to be inconsistent (75,76). This might be explained by the different methods used to measure FA in blood given that they reflect different results (77). Red blood cell (RBC) membranes reflect FA intake over the last 120 days, whereas plasma and serum concentrations of FA reflect the intake of a few prior days (78). Also, it is still uncertain whether FA concentration in blood reflects the concentration of FA in tissues of the central nervous system (51). Most of the studies reviewed measured FA concentration in blood in plasma and only four measured it in RBC membranes. These findings might explain why some studies yielded negative results regardless of the increase in FA concentration in plasma since the increase could only be reflecting the few previous days and not a constant long period.

This systematic review has several limitations such as: a) most of the reviewed RCTs had small sample sizes; b) not all RCTs had the same dosage of omega-3 or duration of intervention; c) baseline cognitive status and assessment of cognitive decline was measured differently among studies; and d) almost none of the studies performed the APOE genotyping.

Regarding previous reviews, meta-analysis and community studies (1,54,71,77,79-83) results have been contradictory. For instance, Burckhardt et al. (2016) (81) found no benefit from n-3 LCPUFA supplementation on cognition; however, this review focused on studies conducted in participants with higher degree of dementia and AD. Additionally, Mazereeuw et al. (2012) (53) suggested a positive effect of n-3 LCPUFAs on the cognitive domains of attention and processing speed on a number of subjects with MCI but not on those with AD. In accordance with the previously mentioned, the results from the only study in this review that included participants with AD were also negative, indicating no effect of n-3 LCPUFA supplementation on cognition. However, most of the conducted reviews on this topic yielded similar results: a possible beneficial effect of n-3 LCPUFA supplementation on cognitive decline (54,83). Nonetheless, just as the studies included in this review, all of them agree on the fact that more RCTs with longer duration and bigger sample size should be conducted for further understanding of the effect of n-3 LCPUFAs on cognition in order to determine an effective and safe therapeutic dosage for cognitive decline.

## CONCLUSION

This systematic review concludes that omega-3 supplementation might have a positive effect on cognition. Thus, n-3 LCPUFAs could be used as a preventive tool for cognitive decline in aged or elder adults or as a therapeutic measure in subjects with cognitive decline. Further studies containing detailed information in regard to duration of the trial, dosage of n-3 LCPUFAs in the supplementation, presence of APOE-ε4 carriers, baseline conditions of the participants, etc., are needed for more accurate information upon the effect of n-3 LCPUFAs supplementation in cognition in elder populations.

## REFERENCES

- Luchtman DW, Song C. Neuropharmacology cognitive enhancement by omega-3 fatty acids from childhood to old age: findings from animal and clinical studies. *Neuropharmacology* 2013;64:550-65.
- Zárate R, El Jaber-Vazdekis N, Tejera N, Pérez JA, Rodríguez C. Significance of long chain polyunsaturated fatty acids in human health. *Clin Transl Med* 2017;6(1):25.
- Bourre JM. Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 1: micronutrients. *J Nutr Heal Aging* 2006;5:377-85.
- Janssen CIF, Kiliaan AJ. Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration. *Prog Lipid Res* 2014;53(1):1-17.
- Calder PC. Docosahexaenoic acid. *Ann Nutr Metab* 2016;69(1):8-21.
- Belkind-Gerson J, Carreón-Rodríguez A, Contreras-Ochoa C, Estrada-Mondaca S, Parra-Cabrera M. Fatty acids and neurodevelopment. *J Pediatr Gastroenterol Nutr* 2008;47(Suppl 1):S7-9.
- Van Goor SA, Janneke Dijk-Brouwer DA, Doombos B, Erwich JJHM, Schaafsma A, Muskiet FAJ, et al. Supplementation of DHA but not DHA with arachidonic acid during pregnancy and lactation influences general movement quality in 12-week-old term infants. *Br J Nutr* 2010;103(2):235-42.
- Stonehouse W. Does consumption of LC omega-3 PUFA enhance cognitive performance in healthy school-aged children and throughout adulthood? Evidence from clinical trials. *Nutrients* 2014;2730-58.
- Yehuda S, Rabinovitz S, Carasso RL, Mostofsky D. The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. *Neurobiol Aging* 2002;23(5):843-53.
- Soderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. *Lipids* 1991;26(6):421-5.
- Bazan NG. Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. *Curr Opin Clin Nutr Metab Care* 2007;10(2):136-41.
- Sarkar D, Fisher PB. Molecular mechanisms of aging-associated inflammation. *Cancer Lett* 2006;236(1):13-23.
- Kidd PM. Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management. *Altern Med Rev* 2005;10:268-93.
- Wu A, Ying Z, Gómez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. *J Neurotrauma* 2004;21(10):1457-67.
- Pifferi F, Jouin M, Alessandri JM, Haedke U, Roux F, Perrière N, et al. n-3 fatty acids modulate brain glucose transport in endothelial cells of the blood-brain barrier. *Prostaglandins Leukot Essent Fatty Acids* 2007;77:279-86.
- Halliwel B. Reactive oxygen species and the central nervous system. *J Neurochem* 1992;59(5):1609-23.
- Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging  $\beta$ -amyloid burden in aging and dementia. *Neurology* 2007;68(20):1718-25.
- Peters R. Ageing and the brain. *Postgrad Med J* 2006;82(964):84-8.
- American Psychiatric Association Committee on Nomenclature and Statistics. *Diagnostic and Statistical Manual of Mental Disorders*. Washington DC; 1994. Available from: <https://jamanetwork.com/journals/jama/article-abstract/379036>

20. Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. *J Intern Med* 2014;275(3):214-28.
21. Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med* 2004;183-94.
22. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L. Mild cognitive impairment - Beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. *J Intern Med* 2004;256(3):240-6.
23. Cire B. World's older population grows dramatically. NIH National Institutes of Health; 2016. Available from: <https://www.nia.nih.gov/news/worlds-older-population-grows-dramatically>
24. Wan H, Goodkind D, Kowal P. An aging world: 2015 international population reports. 2016. Available from: <https://www.census.gov/content/dam/Census/library/publications/2016/demo/p95-16-1.pdf>
25. Solfrizzi V, Moro BA, Universit FP, Moro BA, Universit AC, Moro BA, et al. The role of diet in cognitive decline. *Neural Transm* 2003;110(1):95-110.
26. Leritz EC, McGlinchey RE, Kellison I, Rudolph JL, Milberg WP. Cardiovascular disease risk factors and cognition in the elderly. *Curr Cardiovasc Risk Rep* 2012;5(5):407-12.
27. Myers JS. Factors associated with changing cognitive function in older adults: implications for nursing rehabilitation. *Rehabil Nurs* 2008;33(3):117-23.
28. Danthiir V, Burns NR, Nettelbeck T, Wilson C, Wittert G. The older people, omega-3, and cognitive health (EPOCH) trial design and methodology: a randomised, double-blind, controlled trial investigating the effect of long-chain omega-3 fatty acids on cognitive ageing and wellbeing in cognitively healthy older ad. *Nutr J* 2011;10(1):117.
29. Kirk-Sanchez NJ, McGough EL. Physical exercise and cognitive performance in the elderly: current perspectives. *Clin Interv Aging* 2014;9:51-62.
30. Feinkohl I, Price JF, Strachan MWJ, Frier BM. The impact of diabetes on cognitive decline: potential vascular, metabolic, and psychosocial risk factors. *Alzheimers Res Ther* 2015;7(1):46.
31. Assuncao N, Sudo FK, Drummond C, De Felice FG, Mattos P. Metabolic syndrome and cognitive decline in the elderly: a systematic review. *PLoS One* 2018;13(3):e0194990.
32. Galvin JE. Medical foods and dietary approaches in cognitive decline, mild cognitive impairment, and dementia. In: *Diet and nutrition in dementia and cognitive decline*. Elsevier Inc.; 2015. pp. 343-56. Available from: <https://www.sciencedirect.com/science/article/pii/B9780124078246000318>
33. Chiu C, Su K, Cheng T, Liu H, Chang C, Dewey ME, et al. Progress in neuro-psychopharmacology & biological psychiatry. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. *Prog Neuropsychopharmacol Biol Psychiatry* 2008;32:1538-44.
34. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegaAD study: a randomized double-blind trial. *Arch Neurol* 2006;63:1402-8.
35. Hashimoto M, Kato S, Tanabe Y, Katakura M, Ai Mamum A, Ohno M, et al. Beneficial effects of dietary docosahexaenoic acid intervention on cognitive function and mental health of the oldest elderly in Japanese care facilities and nursing homes. *Geriatr Gerontol* 2016;17(2):330-7.
36. Kotani S, Sakaguchi E, Warashina S, Matsukawa N, Yoshiyuki I, Kiso Y, et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. *Neurosci Res* 2006;56(2):156-64.
37. Van de Rest O, Geleijnse JM, Kok FJ, Van Staveren WA, Dullemeijer C, OldenRikkert MGM, et al. Effect of fish oil on cognitive performance in older subjects. *Neurology* 2008;71(6):430-8.
38. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* 2009;151(4):264-9, W64.
39. Bo Y, Zhang X, Wang Y, You J, Cui H, Zhu Y, et al. The n-3 polyunsaturated fatty acids supplementation improved the cognitive function in the Chinese elderly with mild cognitive impairment: a double-blind randomized controlled trial. *Nutrients* 2017;9(1):1-11.
40. Konagai C, Yanagimoto K, Hayamizu K, Han L, Tsuji T, Koga Y. Effects of krill oil containing n-3 polyunsaturated fatty acids in phospholipid form on human brain function: a randomized controlled trial in healthy elderly volunteers. *Clin Interv Aging* 2013;8:1247-57.
41. Lee LK, Shahar S, Chin A-V, Yusoff NAM. Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. *Psychopharmacology (Berl)* 2013;225(3):605-12.
42. Nilsson A, Radeborg K, Salo I, Bjorck I. Effects of supplementation with n-3 polyunsaturated fatty acids on cognitive performance and cardiometabolic risk markers in healthy 51 to 72 years old subjects: a randomized controlled cross-over study. *Nutr J* 2012;11:99.
43. Stough C, Downey L, Silber B, Lloyd J, Kure C, Wesnes K, et al. The effects of 90-day supplementation with the omega-3 essential fatty acid docosahexaenoic acid (DHA) on cognitive function and visual acuity in a healthy aging population. *Neurobiol Aging* 2012;33(4):2010-2.
44. Witte AV, Kerti L, Hermannstädter HM, Fiebach JB, Schreiber SJ, Schuchardt JP, et al. Long-chain omega-3 fatty acids improve brain function and structure in older adults. *Cereb Cortex* 2013;24(11):3059-68.
45. Tokuda H, Sueyasu T, Kontani M, Kawashima H, Shibata H, Koga Y. Low doses of long-chain polyunsaturated fatty acids affect cognitive function in elderly Japanese men: a randomized controlled trial. *J Oleo Sci* 2015;64(6):633-44.
46. Pase MP, Grima N, Cockerell R, Stough C, Scholey A, Sali A, et al. The effects of long-chain omega-3 fish oils and multivitamins on cognitive and cardiovascular function: a randomized, controlled clinical Trial. *J Am Coll Nutr* 2015;34(1):21-31.
47. Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. *Alzheimer's Dement* 2010;6(6):456-64.
48. Jackson PA, Forster JS, Gordon Bell J, Dick JR, Younger I, Kennedy DO. Dha supplementation alone or in combination with other nutrients does not modulate cerebral hemodynamics or cognitive function in healthy older adults. *Nutrients* 2016;8-86.
49. Boespflug E, McNamara RK, Eliassen J, Schidler M, Krikorian R. Fish oil supplementation increases event-related posterior cingulate activation in older adults with subjective memory impairment. *J Nutr Health Aging* 2016;20(2):161-9.
50. McNamara RK, Kalt W, Shidler MD, McDonald J, Summer SS, Stein AL, et al. Cognitive response to fish oil, blueberry, and combined supplementation in older adults with subjective cognitive impairment. *Neurobiol Aging* 2017;64:147-56.
51. Zhang Y-P, Miao R, Li Q, Wu T, Ma F. Effects of DHA supplementation on hippocampal volume and cognitive function in older adults with mild cognitive impairment: a 12-month randomized, double-blind, placebo-controlled trial. *J Alzheimer's Dis* 2017;55(2):497-507.
52. Phillips MA, Childs CE, Calder PC, Rogers PJ. No effect of omega-3 fatty acid supplementation on cognition and mood in individuals with cognitive impairment and probable Alzheimer's disease: a randomised controlled trial. *Int J Mol Sci* 2015;16(10):24600-13.
53. Mazereeuw G, Lanctôt KL, Chau SA, Swardfager W. Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. *NBA* 2012;33(7):1482.e17-1482.e29.
54. Yurko-Mauro K, Alexander DD, Van Elswyk ME. Docosahexaenoic acid and adult memory: a systematic review and meta-analysis. *PLoS One* 2015;10(3):1-18.
55. Cole GM, Ma QL, Frautschy SA. Omega-3 fatty acids and dementia. *Prostaglandins Leukotriens Essential Fatty Acids* 2009;81(2-3):213-21.
56. Calder PC. Omega-3 fatty acids and inflammatory processes. *Nutrients* 2010;2(3):355-74.
57. Mori TA, Puddey IB, Burke V, Croft KD, Dunstan DW, Rivera JH, et al. Effect of  $\Omega$ 3 fatty acids on oxidative stress in humans: GC-MS measurement of urinary  $F_2$ -isoprostane excretion. *Redox Rep* 2000;5(1):45-6.
58. Akbar M, Calderon F, Wen Z, Kim H-Y. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. *Proc Natl Acad Sci* 2005;102(31):10858-63.
59. Bazan NG. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. *Brain Pathol* 2005;15(2):159-66.
60. Innis SM. Dietary (n-3) fatty acids and brain development. *J Nutr* 2007;137:855-9.
61. Hashimoto M, Hossain S, Shimada T, Shido O. Docosahexaenoic acid-induced protective effect against impaired learning in amyloid  $\beta$ -infused rats with increased synaptosomal membrane fluidity. *Clin Exp Pharmacol Physiol* 2006;33(10):934-9.
62. Litman BJ, Niu S-L, Polozova A, Mitchell DC. The role of docosahexaenoic acid containing phospholipids in modulating G protein-coupled signaling pathways. *J Mol Neurosci* 2001;16(2-3):237-42.
63. Jofre-Monseny L, Minihane A-M, Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. *Mol Nutr Food Res* 2008;52(1):131-45.
64. Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. *Nat Clin Pract Neurol* 2009;5:140-52.

65. Huang Y. Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases. *Curr Opin Lipidol* 2010;21:337-45.
66. Anil E. The impact of EPA and DHA on blood lipids and lipoprotein metabolism: influence of apoE genotype. *Proc Nutr Soc* 2007;66(1):60-8.
67. Cunnane SC, Plourde M, Pifferi F, Bégin M, Féart C, Barberger-Gateau P. Progress in lipid research fish, docosahexaenoic acid and Alzheimer's disease. *Prog Lipid Res* 2009;48(5):239-56.
68. Barberger-Gateau P, Raffaitin C, Letenneur L, Berr C, Tzourio C, Dartigues JF, et al. Dietary patterns and risk of dementia: the Three-City cohort study. *Neurology* 2007;69(20):1921-30.
69. Huang TL, Zandi PP, Tucker KL, Fitzpatrick AL, Kuller LH, Fried LP, et al. Benefits of fatty fish on dementia risk are stronger for those without APOE $\epsilon$ 4. *Neurology* 2005;65(9):1409-14.
70. Whalley L, Deary I, Starr JM, Wahle KW, Rance KA, Bourne VJ, et al. n-3 fatty acid erythrocyte membrane content, APOE  $\epsilon$ 4, and cognitive variation: an observational follow-up study in late adulthood. *Am J Clin Nutr* 2008;87(2):449-54.
71. Cooper ER, Tye C, Kuntsi J. Omega-3 polyunsaturated fatty acid supplementation and cognition: a systematic review and meta-analysis. *J Psychopharmacology* 2015;29(7):753-63.
72. Benisek D, Bailey-Hall E, Oken H, Masayesva S, Arterburn L. Validation of a simple food frequency questionnaire as an indicator of long chain omega-3 intake. In: *Inform 2002; Abstracts of the 93<sup>rd</sup> Annual AOCS Meeting and Expo; 2002; Montreal, Quebec, Canada:S96.*
73. Sinn N, Milte CM, Street SJ, Buckley JD, Coates AM, Petkov J, et al. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. *Br J Nutr* 2012;107(11):1682-93.
74. Shukitt-Hale B, Bielinski DF, Lau F, Willis M. L. The beneficial effects of berries on cognition, motor behaviour and neuronal function in ageing. *Br J Nutr* 2015;114(10):1542-9.
75. Dullemeyer C, Durga J, Brouwer IA, Van de Rest O, Kok FJ, Brummer RJ, et al. n-3 fatty acid proportions in plasma and cognitive performance in older adults. *Am J Clin Nutr* 2007;86(5):1479-85.
76. Beydoun MA, Kaufman JS, Satia JA, Rosamond W, Folsom AR. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study. *Am J Clin Nutr* 2007;85(4):1103-11.
77. Masana MF, Koyanagi A, Haro JM, Tyrovolas S. n-3 fatty acids, Mediterranean diet and cognitive function in normal aging: a systematic review. *Exp Gerontol* 2017;91:39-50.
78. Arab L. Biomarkers of fat and fatty acid intake. *J Nutr* 2003;133:925-32.
79. Weiser MJ, Butt CM, Mohajeri MH. Docosahexaenoic acid and cognition throughout the lifespan. *Nutrients* 2016;8(2):1-40.
80. Morris MC, Evans DA, Tangney CC. Fish consumption and cognitive decline with age in a large community study. *JAMA Neurol* 2005;62(12):1849-53.
81. Burckhardt M, Herke M, Wustmann T, Watzke S, Langer G, Fink A. Omega-3 fatty acids for the treatment of dementia. *Cochrane Database Syst Rev* 2016;4:CD009002.
82. Solfrizzi V, D'Introno A, Colacicco AM, Capurso C, Del Parigi A, Capurso S, et al. Dietary fatty acids intake: possible role in cognitive decline and dementia. *Exp Gerontol* 2005;40(4):257-70.
83. Baleztena J, Arana M, Bes-Rastrollo M, Castellanos MC, Gozalo MJ, Ruiz-Canela M. Does omega-3 supplementation after the age of 65 influence cognitive function? Results of a systematic review. *An Sist Sanit Navar* 2017;40:433-42.